Baseline characteristics of the study population stratified by antiplatelet pretreatment
| Variable | Antiplatelet pretreatment (n=71) | No antiplatelet pretreatment (n=146) | P value |
| Mean±SD age, years | 60±14 | 66±14 | 0.280 |
| Male sex, n (%) | 35 (49) | 73 (50) | >0.999 |
| African-Americans, n (%) | 43 (61) | 84 (58) | 0.769 |
| Hypertension, n (%) | 66 (93) | 100 (68) | <0.001 |
| Diabetes mellitus, n (%) | 37 (52) | 33 (23) | <0.001 |
| Hypercholesterolemia, n (%) | 46 (65) | 31 (21) | <0.001 |
| Atrial fibrillation, n (%) | 22 (31) | 32 (22) | 0.181 |
| Smoking, n (%) | 22 (31) | 41 (28) | 0.750 |
| Median baseline NIHSS score, points (IQR) | 16 (12–21) | 17 (12–20) | 0.699 |
| Median ASPECTS score, points (IQR) | 10 (9–10) | 10 (8–10) | 0.279 |
| Occlusion in posterior circulation, n (%) | 13 (18) | 28 (19) | 0.860 |
| Proximal vessel occlusion, n (%)* | 28 (39) | 73 (50) | 0.149 |
| Presence of tandem occlusions, n (%)† | 7 (10) | 23 (16) | 0.231 |
| Good collateral score on baseline CTA, n (%) | 39 (68) | 65 (54) | 0.072 |
| Intacranial atherosclerotic disease, n (%) | 22 (31) | 48 (33) | 0.780 |
| Intravenous thrombolysis treated, n (%) | 47 (66) | 94 (64) | 0.880 |
| Mean (SD) admission systolic blood pressure, mmHg | 163 (32) | 155 (28) | 0.076 |
| Mean (SD) admission diastolic blood pressure, mmHg | 94 (26) | 88 (19) | 0.093 |
| Mean (SD) admission serum glucose, mg/dL | 152 (61) | 149 (81) | 0.782 |
| Mean (SD) admission low density lipoprotein, mg/dL | 93 (34) | 99 (36) | 0.267 |
| Mean (SD) onset to tPA bolus time, min | 118 (48) | 143 (67) | 0.029 |
| Mean (SD) onset to arterial puncture time, min | 310 (204) | 317 (179) | 0.792 |
*Internal carotid artery or basilar artery occlusion in the anterior and posterior circulation respectively.
†Simultaneous presence of both intracranial and extracranial arterial occlusions in the distribution of acute ischemic stroke.
ASPECTS, Alberta Stroke Program Early CT score; CTA, CT angiography; NIHSS, National Institutes of Health Stroke Scale; IQR: interquartile range; tPA, tissue plasminogen activator.